drugset
drugset / Trial / NCT03882177

StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis

NCT03882177 ↗

Phase 2 Completed 16 enrolled National Institute of Allergy and Infectious Diseases (NIAID)
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of pravastatin adjunctive therapy when combined with the standard tuberculosis (TB) treatment regimen in adults with TB.

Timeline

Start
2020-02-21
Primary completion
2022-05-12
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Pravastatin Small molecule 40 mg Oral
Subject Pravastatin Small molecule 80 mg Oral
Subject Pravastatin Small molecule 120 mg Oral
Subject Pravastatin Small molecule 160 mg Oral
Background Rifafour Unknown — Oral

Indications

pulmonary tuberculosis